{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:57:38Z","timestamp":1790769458151,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.pharmthera.2016.01.004","type":"journal-article","created":{"date-parts":[[2016,1,21]],"date-time":"2016-01-21T11:53:40Z","timestamp":1453377220000},"page":"102-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Current status of data on cangrelor"],"prefix":"10.1016","volume":"159","author":[{"given":"Arman","family":"Qamar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2016.01.004_bb0005","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrcardio.2012.199","article-title":"Antiplatelet therapy: Does prasugrel or ticagrelor suffice in patients with STEMI?","volume":"10","author":"Agrawal","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: Executive summary: A report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2011.2002","article-title":"Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: A randomized controlled trial","volume":"307","author":"Angiolillo","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0020","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11239-012-0737-3","article-title":"Pharmacodynamic effects of cangrelor and clopidogrel: The platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials","volume":"34","author":"Angiolillo","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0025","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0735-1097(00)00777-4","article-title":"Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions: Results in 7,472 octogenarians. National Cardiovascular Network Collaboration","volume":"36","author":"Batchelor","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0030","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1001\/jama.2012.50788","article-title":"Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis","volume":"308","author":"Bellemain-Appaix","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0035","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2009.1249","article-title":"Tailoring antiplatelet therapy based on pharmacogenomics: How well do the data fit?","volume":"302","author":"Bhatt","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0055","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1161\/CIRCRESAHA.114.302737","article-title":"Antiplatelet and anticoagulation therapy for acute coronary syndromes","volume":"114","author":"Bhatt","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0045","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0050","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0040","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.284.12.1549","article-title":"Current role of platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes","volume":"284","author":"Bhatt","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0060","doi-asserted-by":"crossref","first-page":"A1773","DOI":"10.1016\/S0735-1097(15)61773-9","article-title":"Cangrelor in elderly patients undergoing PCI: findings from CHAMPON PHOENIX","volume":"65","author":"Cavender","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0065","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0070","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ahj.2010.01.010","article-title":"Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients","volume":"159","author":"Dauerman","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0075","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.CIR.0000140675.85342.1B","article-title":"Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial","volume":"110","author":"Fox","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0080","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2014.156","article-title":"Novel antiplatelet agents in acute coronary syndrome","volume":"12","author":"Franchi","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2005.11.014","article-title":"Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo-and active-controlled trial","volume":"151","author":"Greenbaum","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0095","article-title":"The effect of cangrelor and access site on ischaemic and bleeding events: Insights from CHAMPION PHOENIX","author":"Gutierrez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0085","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jacc.2013.10.022","volume":"63","author":"G\u0450n\u0450reux","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0100","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0115","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0120","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.thromres.2008.01.021","article-title":"Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction","volume":"122","author":"Heestermans","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0105","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1001\/jama.299.5.532","article-title":"Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome","volume":"299","author":"Ho","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/HPC.0b013e31826c53cd","article-title":"Recommendations for management of antiplatelet therapy in patients undergoing elective noncardiac surgery after coronary stent implantation","volume":"11","author":"Huang","year":"2012","journal-title":"Crit Pathw Cardiol"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0125","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ahj.2012.02.018","article-title":"Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial","volume":"163","author":"Leonardi","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0130","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1136\/heartjnl-2012-303103","article-title":"A novel approach to systematically implement the universal definition of myocardial infarction: Insights from the CHAMPION PLATFORM trial","volume":"99","author":"Leonardi","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0135","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0140","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0145","first-page":"248","article-title":"The efficacy, safety, and net clinical benefit of cangrelor in women undergoing elective or urgent PCI: Insights from the CHAMPION PHOENIX trial","volume":"133","author":"O'Donoghue","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0150","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O'Gara","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0155","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ahj.2009.01.002","article-title":"Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes","volume":"157","author":"Rao","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0160","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.jacc.2013.08.700","article-title":"Radial versus femoral access. (2013)","volume":"62","author":"Rao","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0165","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrcardio.2015.113","article-title":"Switching P2Y12-receptor inhibitors in patients with coronary artery disease","volume":"13","author":"Rollini","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0170","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jcin.2013.08.017","article-title":"Pharmacodynamic effects during the transition between cangrelor and ticagrelor","volume":"7","author":"Schneider","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0175","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/MCA.0000000000000158","article-title":"Pharmacodynamic effects during the transition between cangrelor and prasugrel","volume":"26","author":"Schneider","year":"2015","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0180","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0185","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00228-012-1360-0","article-title":"Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR)","volume":"69","author":"Souckova","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0195","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","article-title":"Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: A pooled analysis of patient-level data","volume":"382","author":"Steg","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0190","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)","volume":"33","author":"Steg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0200","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0210","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/s-0037-1615596","article-title":"Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes","volume":"85","author":"Storey","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0205","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1046\/j.1365-2141.2000.02208.x","article-title":"The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity","volume":"110","author":"Storey","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0215","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/CIR.0b013e31826e1058","article-title":"Third universal definition of myocardial infarction","volume":"126","author":"Thygesen","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0220","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/S0140-6736(15)60292-6","article-title":"Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial","volume":"385","author":"Valgimigli","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0225","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0230","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jacc.2011.09.075","article-title":"Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease","volume":"59","author":"Wang","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0240","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jcin.2014.09.025","article-title":"Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: Insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI])","volume":"8","author":"White","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0235","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ahj.2011.11.001","article-title":"Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction","volume":"163","author":"White","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0245","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/eurheartj\/ehn169","article-title":"Clopidogrel pre-treatment in stable angina: For all patients >6h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8","volume":"29","author":"Widimsky","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0250","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.01.004_bb0255","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372581600005X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372581600005X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T18:08:13Z","timestamp":1567534093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016372581600005X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":51,"alternative-id":["S016372581600005X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.01.004","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current status of data on cangrelor","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}